Notably, inhibitors such as the BET protein inhibitor GSK525762, the AURKA inhibitor MLN8237, and the ODC inhibitor DFMO are currently undergoing clinical evaluation for MYCN-driven cancers. The gene discussed is MYCN; the disease is cancer.